BNTC (Benitec Biopharma) Beta: -0.7957 (As of Jun. 25, 2026)


BNTC Benitec Biopharma Inc BNTC
34 GF Score
Price $13.00
View Full Analysis

What is Benitec Biopharma Beta?

Benitec Biopharma BNTC -5.01% 34 Beta is -0.7957 as of Jun. 25, 2026. GuruFocus rates BNTC with a GF Score™ of 34/100.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Benitec Biopharma's Beta is -0.7957.


Benitec Biopharma  (NAS:BNTC) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Benitec Biopharma Beta Related Terms


Benitec Biopharma Beta Historical Data

* Premium members only.

The historical data trend for Benitec Biopharma's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Benitec Biopharma Beta Chart

Benitec Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.37 1.45 1.01 0.36 -0.38

Benitec Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 -0.38 -1.55 -1.45 -0.98

BNTC vs OABI, FBRX, LXEO: Beta Comparison

For the Biotechnology subindustry, Benitec Biopharma's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Beta distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Beta falls into.


BNTC
34GF Score
Benitec Biopharma Inc BNTC
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Benitec Biopharma Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.7957 mean?
Benitec Biopharma (BNTC) has a Beta of -0.7957 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Benitec Biopharma and its competitors.
Is Benitec Biopharma's Beta too high?
Benitec Biopharma's current Beta is -0.7957. Overall, Benitec Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Benitec Biopharma's Beta compare to OABI and FBRX?
Benitec Biopharma's Beta of -0.7957 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Benitec Biopharma and its competitors. Benitec Biopharma's current Beta is -0.7957. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Benitec Biopharma stock overvalued right now?
Benitec Biopharma (BNTC) has a current Beta of -0.7957. The current Beta is -0.7957. Benitec Biopharma's overall GF Score™ is 34/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Benitec Biopharma (BNTC), the current Beta is -0.7957 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Benitec Biopharma Business Description

Address 3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
34GF Score

Get the complete analysis for BNTC

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.00
Price